KNSA Kiniksa Pharmaceuticals Ltd

Analysts have given Kiniksa Pharmaceuticals International (NASDAQ:KNSA) an average rating of "Moderate Buy," with an average 12-month target price of $52.00. Despite this positive outlook, the company has seen significant insider selling, totaling $21.58 million over the past 90 days. Kiniksa's recent quarterly results showed increased revenue but missed EPS estimates, with analysts forecasting a negative EPS for the current year.

Two Kiniksa Pharmaceuticals executives, Barry D. Quart and Tessari Eben, recently sold a significant number of Class A Ordinary Shares. Both transactions occurred on December 15, 2025, and were executed as part of 10b5-1 plans, totaling over $1.3 million in sales. Following these sales, both individuals still retain direct ownership of Kiniksa Pharmaceuticals shares.

Barry Quart, a Director at Kiniksa Pharmaceuticals International (NASDAQ:KNSA), sold 20,129 shares of the company's stock on December 15th, 2025, for a total of $835,554.79. This transaction reduced his direct ownership to 12,546 shares. The article also provides a company profile, recent price performance, institutional trading activity, and analyst ratings for Kiniksa Pharmaceuticals International.

Braidwell LP has reduced its stake in Kiniksa Pharmaceuticals International (NASDAQ:KNSA) by 43.8%, selling 860,329 shares and now owning 1,102,580 shares valued at approximately $30.5 million. This follows significant insider sales totaling over $20 million in the past three months, although corporate insiders still hold a substantial 53.48% of the stock. Despite these sales, analysts maintain a "Moderate Buy" rating for KNSA with an average price target of $52.00, while the stock trades near its 52-week high with a market cap of $3.15 billion.

Nebula Research & Development LLC significantly increased its stake in Kiniksa Pharmaceuticals International, plc (KNSA) by 82.4% to $1.93 million, now owning 69,884 shares, as institutional investors collectively hold about 53.95% of the company. Despite this, company insiders have been net sellers, offloading over half a million shares worth approximately $20.84 million in the last 90 days. Analysts maintain a "Moderate Buy" rating with a consensus price target of $52, while the company reported a 61.2% year-over-year revenue increase but missed EPS estimates for the last quarter.

Jump Financial LLC has acquired a new position in Kiniksa Pharmaceuticals International, plc, purchasing 226,038 shares valued at approximately $6.25 million. This move is juxtaposed with significant insider selling from top executives, totaling over $19 million in the last three months. Despite missing EPS estimates, Kiniksa's revenue grew over 61% year-over-year, and analysts maintain a "Moderate Buy" rating with a consensus price target of $52.00.